# Beyond muscle weakness: pathogenesis of sepsis-induced myopathy and its management

## TL;DR

This paper reviews the causes and treatments of sepsis-induced myopathy, emphasizing the need for integrated molecular and rehabilitation strategies to improve patient outcomes.

## Contribution

The paper provides a comprehensive review of molecular mechanisms and emerging therapies for sepsis-induced myopathy.

## Key findings

- Current management includes infection control, inflammation modulation, and structured rehabilitation.
- Emerging therapies like stem cell therapy and gene-editing show promise for treating SIM.
- Personalized medicine approaches may enhance recovery and quality of life for patients.

## Abstract

Sepsis-induced myopathy (SIM)significantly contributes to long-term disability and mortality among sepsis survivors. A comprehensive understanding of both the molecular mechanisms and rehabilitation strategies is crucial for effective management.

A review of pertinent studies was conducted, focusing on the molecular pathogenesis, therapeutic strategies, and rehabilitation interventions for SIM, with particular attention to clinical and translational advancements.

Current management strategies encompass infection control, modulation of inflammation, nutritional support, and structured rehabilitation programs, including early mobilization and physiotherapy. Emerging therapies that target inflammation, cellular protection, and regeneration – such as stem cell therapy and gene-editing techniques – demonstrate potential. Furthermore, advancements in personalized medicine, including genomics, transcriptomics, and individualized metabolic interventions, may further improve outcomes.

Optimizing both mechanistic and rehabilitation strategies is essential for enhancing functional recovery and quality of life in patients with SIM. An integrated clinical and molecular approach presents the most promising path forward. Keywords: sepsis-induced myopathy, sepsis.